Cargando…

Multiple sclerosis

Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature. The cause is unknown; both genetic and environmental factors have been implicated in the pathogenesis. MS generally p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Sharon G., Rose, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Mosby, Inc. 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130340/
https://www.ncbi.nlm.nih.gov/pubmed/8556963
http://dx.doi.org/10.1016/S0011-5029(96)90012-7
_version_ 1783516989144170496
author Lynch, Sharon G.
Rose, John W.
author_facet Lynch, Sharon G.
Rose, John W.
author_sort Lynch, Sharon G.
collection PubMed
description Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature. The cause is unknown; both genetic and environmental factors have been implicated in the pathogenesis. MS generally presents with the acute or subacute onset of neurologic abnormalities that may wax and wane over many years. Diagnosis is generally made by means of observation of the clinical course in conjunction with a neurologic examination and laboratory tests. These tests may include magnetic resonance imaging of the head and spine, lumbar puncture, and evoked potentials. Treatment is based on general supportive care, the use of corticosteroids for relapses, and symptomatic management of ongoing problems. The frequency of relapses can be reduced with interferon-β (Betaseron). Copolymer 1 and interferon-β la are being evaluated by the U.S. Food and Drug Administration for approval for use for reduction in the frequency of relapses in relapsing-remitting MS. Treatment of chronic progression is often attempted with immunosuppressive agents such as corticosteroids, azathioprine, and cyclophosphamide. Use of other agents is being investigated.
format Online
Article
Text
id pubmed-7130340
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Published by Mosby, Inc.
record_format MEDLINE/PubMed
spelling pubmed-71303402020-04-08 Multiple sclerosis Lynch, Sharon G. Rose, John W. Dis Mon Article Multiple sclerosis is a chronic disease that begins in late adolescence or adulthood. It is highly variable in its expression and severity. It is believed to be autoimmune in nature. The cause is unknown; both genetic and environmental factors have been implicated in the pathogenesis. MS generally presents with the acute or subacute onset of neurologic abnormalities that may wax and wane over many years. Diagnosis is generally made by means of observation of the clinical course in conjunction with a neurologic examination and laboratory tests. These tests may include magnetic resonance imaging of the head and spine, lumbar puncture, and evoked potentials. Treatment is based on general supportive care, the use of corticosteroids for relapses, and symptomatic management of ongoing problems. The frequency of relapses can be reduced with interferon-β (Betaseron). Copolymer 1 and interferon-β la are being evaluated by the U.S. Food and Drug Administration for approval for use for reduction in the frequency of relapses in relapsing-remitting MS. Treatment of chronic progression is often attempted with immunosuppressive agents such as corticosteroids, azathioprine, and cyclophosphamide. Use of other agents is being investigated. Published by Mosby, Inc. 1996-01 2004-03-12 /pmc/articles/PMC7130340/ /pubmed/8556963 http://dx.doi.org/10.1016/S0011-5029(96)90012-7 Text en Copyright © 1996 Published by Mosby, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lynch, Sharon G.
Rose, John W.
Multiple sclerosis
title Multiple sclerosis
title_full Multiple sclerosis
title_fullStr Multiple sclerosis
title_full_unstemmed Multiple sclerosis
title_short Multiple sclerosis
title_sort multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130340/
https://www.ncbi.nlm.nih.gov/pubmed/8556963
http://dx.doi.org/10.1016/S0011-5029(96)90012-7
work_keys_str_mv AT lynchsharong multiplesclerosis
AT rosejohnw multiplesclerosis